Industry News

• Seasoned financial executive Federica O'Brien joins GT Biopharma's board of directors  GT Biopharma announced the addition of Federica O'Brien, CPA to GT Biopharma's board of directors. Ms. O'Brien has held the Chief Financial Officer position at Complexa, Cerecor, and Cardiokine, and was Corporate Controller at Barrier Therapeutics.
  April 26, 2018  
• Bayer signs agreement to sell Crop Science businesses to BASF for up to 1.7 billion  In light of the proposed acquisition of Monsanto, Bayer has signed an agreement to sell further Crop Science businesses to BASF for up to 1.7 billion euros. The businesses to be sold generated total sales of 745 million euros in 2017.
  April 26, 2018  
• Two-year feasibility study results encouraging with Medtronic Harmony(TM) transcatheter  Medtronic announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve from its early feasibility study. Designed to offer a treatment alternative for patients with CHD, the Harmony TPV is being studied in CHD patients born with RVOT anomalies who undergo surgical repair early in life.
  April 26, 2018  
• Alder BioPharmaceuticals® appoints Jeremy Green to its board of directors  Alder Biopharmaceuticals announced that its Board of Directors has unanimously appointed Jeremy Green, Founder and Portfolio Manager of Redmile Group, to the Company’s Board. Mr. Green will serve as a Class III director with a term expiring at the Company’s 2020 Annual Meeting.
  April 26, 2018  
• EnWave announces commercial launch of iogo protein crunchy yogurt bites  EnWave announced that Agropur Dairy Co-operative d.b.a. Ultima Foods, a royalty-partner of the Company, has successfully developed a new, innovative way of enjoying yogurt on-the-go and will be soft launching its iö:go Protein Crunch snack products in Quebec and Alberta this Spring.
  April 26, 2018  
• Achaogen wins CARB-X funding award to advance development of novel aminoglycoside  Achaogen announced it has entered into an award agreement with CARB-X. Under the agreement, Achaogen will receive an initial award of up to $2.4 million, with the possibility of up to $9.6 million more from CARB-X at its discretion based on the achievement of certain project milestones.
  April 26, 2018  
• INSYS Therapeutics and UC San Diego Center for Medicinal Cannabis Research to collaborate  NSYS Therapeutics announced a collaboration with the University of California San Diego School of Medicine’s Center for Medicinal Cannabis Research to study cannabidiol as a potential treatment for severe symptoms of autism in pediatric patients.
  April 26, 2018  
• BioSig Technologies to partner with High Lantern Group  BioSig Technologies announced that it has appointed High Lantern Group to assist in building a global stakeholder engagement strategy as the Company prepares for commercialization of its PURE EP(tm) System.
  April 26, 2018  
• Endo to acquire Somerset Therapeutics and business af affiliate Wintac for $190 million  Endo announced definitive agreements to acquire Somerset Therapeutics, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs, and the business of its India based affiliate Wintac Limited. Endo is paying approximately $190 million.
  April 26, 2018  
• Corvus Pharmaceuticals announces initiation of phase 1/1b clinical trial  Corvus announced it is enrolling patients in a multicenter Phase 1/1b clinical trial of CPI-006, a humanized monoclonal antibody directed against CD73. The three-arm study in patients with a variety of solid tumors is evaluating CPI-006 administered as a single agent, in combination with CPI-444.
  April 26, 2018  

   (next 10 articles)